0TDD.L
NOVO NORDISK A/S NOVO-NORDISK A
£44.24
-2.88%
2026-06-01
About NOVO NORDISK A/S NOVO-NORDISK A
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Key Fundamentals
P/E Ratio
0.15
EPS (TTM)
£3.03
ROE
71.4%
Revenue Growth (YoY)
24.0%
Profit Margin
37.2%
Debt/Equity
72.09
Price/Book
6.39
Beta
0.35
Market Cap
£93.14B
Avg Volume (10D)
27K
Recent Breakout Signals
No recent breakout signals detected for 0TDD.L.
Recent Price Range (60 Days)
60D High
£48.90
60D Low
£35.09
Avg Volume
173K
Latest Close
£44.24
Get breakout alerts for 0TDD.L
Sign up for Breakout Scanner to receive daily notifications when 0TDD.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
NOVO NORDISK A/S NOVO-NORDISK A (0TDD.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0TDD.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.